# Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes

Study · id `cardio:ct-nct01862263` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01862263](<https://clinicaltrials.gov/study/NCT01862263>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01862263

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 191 participants.

## Technical summary

Registry record NCT01862263. Randomized; double masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 191 participants (enrolled count; ClinicalTrials.gov record NCT01862263, source copy `cardio:ctgov-nct01862263-2019-06-05`, retrieved 2026-10-26)
- Start date: 2013-05 (registry gives no type) (ClinicalTrials.gov record NCT01862263, source copy `cardio:ctgov-nct01862263-2019-06-05`, retrieved 2026-10-26)
- Primary completion: 2015-07 (actual) (ClinicalTrials.gov record NCT01862263, source copy `cardio:ctgov-nct01862263-2019-06-05`, retrieved 2026-10-26)
- Completion: 2015-07 (actual) (ClinicalTrials.gov record NCT01862263, source copy `cardio:ctgov-nct01862263-2019-06-05`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT01862263, source copy `cardio:ctgov-nct01862263-2019-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01862263-2019-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
- Acronym: VIDA
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Vildagliptin
- Intervention (Drug): Insulin
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 2ff8a9e0f1a3ce20d0b9a5e91b45ad9e2f9d6219447b420f9b682b0be9ca6151
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
